# A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Source: https://onco.cc/trials/nct06228326/  
OnCo record `nct06228326` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Docetaxel in metastatic cancer, run by Krystal Biotech, Inc., now recruiting.

## Summary

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs is a phase 1/2 interventional study registered as NCT06228326 by Krystal Biotech, Inc., with 250 participants planned, started 2024-04-17 and due to reach its primary completion in 2027-02. Interventions recorded: KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel. Conditions listed: Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06228326
- Phase: 1/2
- Setting: KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs
- Sponsor: Krystal Biotech, Inc.
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT06228326: https://clinicaltrials.gov/study/NCT06228326

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Krystal Biotech](https://onco.cc/companies/krystal-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct06228326.json